Iovance Biotherapeutics Inc.

3 days ago · globenewswire.com

SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 17, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 179,750 shares of Iovance's common stock to eighteen new, non-executive employees.

5 days ago · defenseworld.net

Iovance Biotherapeutics (NASDAQ: IOVA - Get Free Report) and eXoZymes (NASDAQ: EXOZ - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Analyst Recommendations This is a breakdown of current ratings

7 days ago · defenseworld.net

Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $9.41 and last traded at $9.26, with a volume of 21030162 shares. The stock had previously closed at $8.60. Analysts Set New Price Targets A number of brokerages

18 days ago · globenewswire.com

SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:

1 month ago · benzinga.com

Shares of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) are trending Friday morning, continuing a momentum surge that recently pushed the biotech stock to a new 52-week high after gaining over 250% year-to-date.

1 month ago · benzinga.com

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is trading at a 52-week high on Thursday, despite having no news to justify the move. Year to date, the stock has surged over 200%.

1 month ago · zacks.com

Does Iovance Biotherapeutics (IOVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago · seekingalpha.com

Iovance Biotherapeutics, Inc. delivered a breakout Q2 '26 for Amtagvi sales, with management guiding for further growth ahead. IOVA's maturing clinical pipeline and imminent NSCLC readout position the company for further upside, given the market potential in NSCLC is several times larger than in melanoma. Potential competitor, IMTX, is expecting to produce results from a trial of its cell therapy, Anzu-cel, in melanoma in H1 '27.

1 month ago · fool.com

Iovance's revenue rose 66% last quarter due to strong demand for Amtagvi. The company also cut its losses by nearly 60%.

2 months ago · zacks.com

Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.